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Abstract. The present study was designed to investigate the
effects of fermented miso (fermented soybean paste) on the
induction of colon tumors by azoxymethane (AOM) in male
F344 rats. A total of 91 rats, 6 weeks of age, were divided
into 5 groups and given weekly subcutaneous injections of
AOM (15 mg/kg body wt) for 3 weeks. The animals were
placed on diets one week before the first AOM dose:
commercial normal control MF diet or a diet containing 10%
2-year, 180-day fermented, or 3-4-day fermented miso. There
were no differences in body and organ weights, and no
aberrant crypt foci (ACF) among carcinogen-treated groups at
week 25. The rates of tumor incidence were 45%, 85%, 75%
and 60% with the 2-year, 180-day, and 3-4-day fermented
miso and MF, respectively, and those for colon tumors were
34%, 55%, 60% and 55%, respectively. The size of well-
differentiated adenocarcinomas and total (well differentiated
and signet ring cell) adenocarcinomas in the 180-day
fermented miso group was significantly smaller than that in
the 2-year fermented miso and MF+AOM groups. Nuclear
staining of ß-catenin in colon tumors was increased for the 3-
4-day fermented miso compared to the 180-day fermented
miso. Cdx2 staining tendency was decreased in colon tumors
and adenocarcinomas compared to normal mucosa and ACF,
which stained in 100% of cases. In addition, the PCNA index
was significantly reduced in the 180-day group compared with
those groups receiving the 3-4-day fermented miso and MF
diet. The germinal region was also decreased. The present
results indicate that dietary supplementation with 180-day
fermented dietary miso could act as a chemopreventive agent
for colon carcinogenesis.
Introduction
The incidence of breast and prostate cancer in Asian countries
with a high consumption of soy and soy-based products is
lower than the United States. However, the rates for these
cancers have shown an increase in the second generation of
families that migrate to America from these countries as their
diet becomes westernized (1). Thus, environment (lifestyle)
may have a greater influence than genetic background. Miso,
a traditional ingredient of the Japanese diet, is fermented
from soybeans, rice, wheat or oats, and its major constituents
are vitamins, microorganisms, salt, minerals, plant proteins,
carbohydrates, and fat. It is used on a daily basis to flavor
food in Japan and other parts of Asia, and remains an
essential ingredient for Japanese style cooking. We have
described chemopreventive effects of miso against intestinal
injury in X-irradiated mice (2), and it has also been reported
to reduce the occurrence of liver (3,4) and gastric tumors (5),
as well as the development of aberrant crypt foci (ACF) in
experimental animals in a dose-dependent manner (6).
However, the effects of soy beans and related foodstuffs on
cancer risk are complex (7). Recently, our experimental
studies provided evidence that long-term fermented miso is
quite effective in aiding the recovery of stem cells in the
small intestinal crypts after irradiation (8), and decreasing the
development of azoxymethane (AOM)-induced ACF (9),
gastric tumors induced by N-methyl-N'-nitro-N-nitroso-
guanidine (10) and pulmonary adenocarcinomas induced by
dipropanolnitrosamine (11). To determine whether soy beans
alone or fermentation processes have a role, the present study
was performed to assess the chemopreventive potential of
samples after different periods of fermentation.
Materials and methods
Animals. Male F344/DuCrj rats, 5 weeks of age at commence-
ment, were purchased from Charles River and housed five to
a polycarbonate cage under a constant temperature of 24±2˚C
and relative humidity of 55±10%, with a 12:12-h light-dark
cycle. The animals were maintained according to the Guide
for the Care and Use of Laboratory Animals established
by Hiroshima University. All were given free access to a
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commercial diet (MF; Oriental Yeast Co., Tokyo, Japan) alone
or with added miso. Dry red miso after 2 years, 180 days or
3-4-days fermentation was supplemented using biscuits at
10% w/w (Miso Central Institute, Tokyo, Japan). Normal tap
water was also provided ad libitum.
Carcinogen. AOM was purchased from Sigma Chemical Co.
(St. Louis, MO).
Experimental procedure. A total of 91 rats were divided into
5 groups. Starting at 6 weeks of age, the initiated groups were
given weekly subcutaneous injections of AOM (15 mg/kg
body weight) for 3 weeks to induce colon tumors. One
week before the first AOM dose, the rats were fed test and
control diets, then sacrificed 25 weeks after the last AOM
injection. Autopsy was performed under ether anesthesia
at which time the body and major organ weights were
measured.
Experimental groups. Animals in carcinogen-initiated groups
1-4 were fed diets containing 10% miso fermented for 2
years, 180 days and 3-4-days and MF diet, respectively,
while control group 5 received only the MF diet.
Visualization and histological examination. Upon termination
of the studies, each colon was removed, flushed with saline,
longitudinally slit open from cecum to anus, placed on a
paper towel and fixed in 10% buffered formalin for 24 h.
Following the protocol cited by Magnuson and Bird (12), the
fixed colons were stained with 0.5% methylene blue for 15-
30 min, then placed on a glass slide with the luminal side up.
Viewing the stained colons under a light microscope at a
magnification of x20-30, the presence of ACF was assessed
to determine the number of ACFs per colon, ACs per colon,
and ACs per focus. Histological evaluation was performed
using routine procedures with H&E staining. Tumors were
classified into three types: microadenomas, adenomas and
adenocarcinomas, with the latter featuring displastic cells
invading the muscularis mucosa or beyond (13). 
Immunohistochemistry. An anti-PCNA antibody (Dako Co.,
Kyoto, Japan) was used with the avidin-biotin complex
method for assessment of cellular proliferation. Tissue
sections were deparaffinized with xylene, hydrated through a
graded ethanol series and incubated with 0.3% hydrogen
peroxide for 30 min to block endogenous peroxidase activity.
They were incubated with 10% normal house serum at room
temperature for 30 min to block background staining and
with primary antibodies against ß-catenin (diluted 1:100;
Transduction Laboratories, BD 610153, KY), Cdx2 (diluted
1:50; Biogenex CDX2-88) (14) or monocolonal mouse anti-
proliferating cell nuclear antigen antibody (diluted 1:200;
Dako-PCNA, PC 10, code no. M 879) for 1 h at room
temperature. The locations of the nearest and farthest PCNA-
positive cells from the bed of the crypt were defined as the
base, and top, and the distance between them was measured
as the germinal region (15). Cell numbers observed in single
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Table I. Dietary intake and drinking water per day per rat.
–––––––––––––––––––––––––––––––––––––––––––––––––
Diet Water
Group (g/day/rat) (ml/day/rat)
–––––––––––––––––––––––––––––––––––––––––––––––––
2-year fermented miso+AOM 12.2±0.7c 24.4±3.0a,c
180-day fermented miso+AOM 12.5±0.9c 23.1±3.2a,c
3-4-day fermented miso+AOM 12.4±0.9c 21.7±2.2a,c
MF+AOM 12.7±0.6b 16.4±2.5
MF control 13.4±1.0 17.2±3.1
–––––––––––––––––––––––––––––––––––––––––––––––––
Mean ± SD. aSignificantly different from MF+AOM value (P<0.01).
bSignificantly different from MF value (P<0.05). cSignificantly
different from MF value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Body and organ weights (relative weights).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
No. of Body weight
Group rats (g) Liver (g) Kidney (g) Testis (g) Spleen (g)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
2-year fermented miso+AOM 20 360.7±19.00b 9.1±0.8b 2.10±0.14 3.32±0.59 0.680±0.043
(2.52±0.13b) (0.58±0.03) (0.92±0.16) (0.19±0.01)
180-day fermented miso+AOM 20 371.7±26.62a 9.8±0.9b 2.10±0.17 3.29±0.12 0.734±0.204
(2.64±0.16) (0.57±0.03) (0.89±0.06) (0.20±0.07)
3-4-day fermented miso+AOM 20 373.1±21.80a 9.5±0.8b 2.02±0.13b 3.26±0.11 0.705±0.057
(2.56±0.15b) (0.54±0.03) (0.88±0.05) (0.19±0.02)
MF+AOM 20 365.8±17.30b 9.1±0.6b 2.05±0.14b 3.22±0.25 0.057±0.780
(2.49±0.15b) (0.56±0.03) (0.88±0.07) (0.24±0.21)
MF control 11 390.6±17.10 10.7±0.7 2.22±0.17 3.38±0.11 0.688±0.052
(2.74±0.12) (0.57±0.04) (0.87±0.04) (0.18±0.01)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Mean ± SD. There are not significantly different among AOM groups. aSignificantly different from MF value (P<0.05). bSignificantly
different from MF value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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half crypts, from the beds of crypts to the surface, were
counted and converted into % values for bottom and top
positions. Numbers of positively stained nuclei were counted
and divided by the total number of nuclei to give the PCNA
index (%). ß-catenin- and Cdx2-positive nuclei numbers
were also counted and divided by the total epithelial cells in
tumors to give indices for nuclear accumulation. 
Statistics. Statistical significance was determined with the
Dunnett's method for multiple comparisons using logarithmic
transformation and the Student's t-test.
Results
General observations. Diet intake was significantly decreased
in the AOM groups, and drinking water increased in the miso
groups (Table I). Final body and organ weights are shown in
Table II, with increased values for the MF group compared to
the other groups. Average body and liver weights of rats in
the AOM groups were significantly different compared with
the MF groups. Kidney weights in the 3-day fermented miso
and MF+AOM groups also differed significantly from the
MF values, but no variation was evident for testis or spleen
weights. Relative liver weights (organ weight/body weight
x100) in the 2-year and 3-day fermented miso and MF+AOM
groups were significantly decreased compared with the MF
group values. There were no differences in body and organ
weights among carcinogen-treated groups at week 25.
Colonic ACF. Table III summarizes data for the mean numbers
of ACF per colon, total number of AC per colon and mean
number of AC per focus using surviving animals. All rats
treated with AOM showed a 100% incidence. The average
number of ACF per colon, and total AC number and number
of AC per focus was not significant among carcinogen-treated
groups. 
Tumor induction. Three animals with duodenum signet cell
carcinomas died 103, 149 and 163 days after the first AOM
injection in miso groups. The total colon tumor incidence
in the 2-year fermented miso group was decreased 45%
compared with the control group, as shown in Table IV.
Signet ring cell carcinomas in the large intestine were not
found in the 180-day fermented miso group. Tumor size upon
macroscopic observation in the 180-day fermented miso group
was significantly decreased compared with the 2-year
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Table III. Number of ACFs in macroscopic findings.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Group No. of rats ACFs Total ACs Mean of ACs
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
2-year fermented miso+AOM 19 118.5±47.6b 375.5±163.5b 3.2±0.4
180-day fermented miso+AOM 19 98.6±58.6b 316.3±194.8b 3.2±0.4
3-4-day fermented miso+AOM 19 114.6±47.6b 365.2±153.7b 3.2±0.4
MF+AOM 20 101.0±48.2b 298.6±148.9b 3.0±0.3
MF control 11 2.2±3.1 1.1±1.2 4.5±6.1
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Mean ± SD. There was not significantly different among AOM groups. aSignificantly different from MF value (P<0.05). bSignificantly
different from MF value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table IV. Incidence of tumors.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Colon tumors in rats
––––––––––––––––––––––––––––––––––––
Total Rats Adenocarcinoma
no. with ––––––––––––––––––
Group of rats tumors Total Adenoma Differentiated Signet Duodenal tumor
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
2-year fermented miso+AOM 20 9 (45) 7 (35) 2 (10) 4 (20) 1 (5) 2 (10): 1 adenocarcinoma,
1 signet ring cell carcinoma
180-day fermented miso+AOM 20 17 (85) 11 (55) 5 (25) 6 (30) 0 8 (40): 1 adenoma,
6 adenocarcinoma,
1 signet ring cell carcinoma 
3-4-day fermented miso+AOM 20 15 (75) 12 (60) 0 9 (45) 3 (15) 3 (15): 2 adenoma, 1 signet
ring cell carcinoma
MF+AOM 20 12 (60) 11 (55) 2 (10) 7 (35) 2 (10) 2 (10): 1 adenocarcinoma,
1 signet ring cell carcinoma
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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fermented miso group (Table V). Upon microscopic
observation, the size of differentiated adenocarcinomas and
total adenocarcinomas (well-differentiated and signet ring
cell) in the 180-day and 3-4-day fermented miso groups was
significantly smaller than in the 2-year fermented miso and
MF+AOM groups. Duodenum tumors in the 180-day
fermented miso group showed a tendency to be increased.
Cell proliferation. PCNA-labeling indices for cell proliferation
in the distal colon are given in Table VI. Significant variation
in cell number for half crypts, numbers of PCNA-positive
cells, highest position of cells and width of the germinal region
in the 2-year and 180-day fermented miso groups were
significantly decreased compared with the MF+AOM values.
ß-catenin staining. Some normal and tumor specimens were
examined with ß-catenin immunohistochemistry. In normal
colon mucosa, immunostaining revealed ß-catenin to be
mainly localized at the cell membranes of surface epithelial
cells. Cytoplasmic and nuclear immunostaining was observed
in microadenomas, adenomas and adenocarcinomas, but not
in ACFs. The cytoplasmic staining was homogeneous, while
both homogeneous and heterogeneous patterns were noted
for nuclei. The index or ß-catenin-positive nuclei in the 3-4-day
fermented miso group was significantly larger than the
180-day fermented miso value (P<0.05) (Table VII). 
Cdx2. Some normal and tumor specimens were examined
with Cdx2 immunostaining. Generally, normal mucosa and
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Table V. Number of colon tumor per rat and tumor size.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Adenocarcinoma
No. of colon Mean Differentiated (differentiated +
tumors tumor adenocarcinoma signet ring cell)
Group per rat size (mm) size (mm) size (mm)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
2-year fermented miso+AOM 0.50±0.83 5.77±5.56 9.72±5.43a 11.40±6.37
180-day fermented miso+AOM 0.85±1.04 2.77±3.01a,b 3.56±2.56a,c 3.56±2.56a,b
3-4-day fermented miso+AOM 0.95±1.05 2.68±2.18a,b 3.66±2.45a,c 7.97±9.24
MF+AOM 1.10±1.30 4.32±3.81 6.86±3.38 7.26±3.51
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Mean ± SD. aSignificantly different from AOM value (P<0.05). bSignificantly different from 2-year fermented miso+AOM value (P<0.05).
cSignificantly different from 2-year fermented miso+AOM value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table VI. Cell proliferation in colonic mucosa without tumors.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
No. of No. of PCNA- Labeling Lowest Highest Germinal
Group cells positive cells index cell position cell position region
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
2-year fermented miso+AOM 26.6±4.2d 5.6±2.6d 21.3±9.4d 2.8±2.4 16.1±4.7d 49.8±18.0d
180-day fermented miso+AOM 26.6±4.3d 4.8±2.4d 18.2±8.8d 3.2±2.4c 14.7±5.6d 42.8±22.6d
3-4-day fermented miso+AOM 28.3±5.9 11.2±4.7b 39.7±14.2b 2.5±2.9 20.1±4.9b 62.6±15.6b
MF+AOM 29.9±4.8a 10.4±3.9b 35.5±12.6b 2.3±1.7 20.2±4.4b 60.0±12.7b
MF 27.3±3.3 5.8±2.2 21.7±9.3 2.7±3.1 15.2±3.4 45.6±13.2
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Mean ± SD. aSignificantly different from MF value (P<0.05). bSignificantly different from MF value (P<0.01). cSignificantly different from
MF+AOM value (P<0.05). dSignificantly different from MF+AOM value (P<0.01).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table VII. ß-catenin-positive tumors.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Group Total cases Negative Nucleus Cytoplasm Nucleus + cytoplasm
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
2-year fermented miso+AOM 10 2 (20) 7 (70) 0 1 (10)
180-day fermented miso+AOM 21 11 (52) 6 (29)a 3 (14) 1 (5)
3-4-day fermented miso+AOM 21 8 (38) 13 (61)a 0 0
MF+AOM 20 9 (45) 11 (55) 0 0
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aSignificantly different (P<0.05).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Ohuchi 30_5  9/11/2005  18:43  ™ÂÏ›‰·1562
ACF were positive in all nuclei, and positive rates decreased
through microadenomas and adenomas to adenocarcinomas
(Table VIII). Negative staining in nuclei was elevated with
the 3-4-day fermented miso (6/8) compared with the 180-day
fermented miso (1/4). 
Discussion
In the present study, dietary administration of 180-day
fermented miso, but not 2-year or 3-4-day fermented miso,
inhibited the development of AOM-induced colon adeno-
carcinomas in the rat colon. In epidemiological studies,
Watanabe et al reported that rectal tumors were significantly
decreased by both intake of soy beans and tofu, but some
authors have described no inhibition or even an increase
associated with miso intake (16). Poole et al found rectal
tumors to be decreased by tofu and soybean in the U.S. (17),
while Hu et al reported reduced rectal, but not colon tumors
in China (18). LeMarchard et al presented evidence of a
gender-dependence, with tofu intake in Hawaii being linked
to decreased colon tumors in females, but not in males (19).
Adenoma of the sigmoid colon was decreased by miso soup,
and colon tumors were decreased dose dependently by tofu
and soy products in the U.S. or by isoflavone and soy protein
in both males and females in Japan (19). Tuyns et al reported
soybeans to be clearly protective against colon rectal cancers
on the basis of a case control study in Belgium (20). 
In animal experiments, however, Davies et al found no
protection when 6-week-old male Fisher 344 rats were fed
diets high in fat and low in calcium with soy protein with
varying isoflavone contents one week before to 31 weeks
post-AOM treatment, and soy high in isoflavones did not
protect against the development of colon tumors in AOM-
treated rats fed a high fat, high risk diet (21). Similarly,
development of intestinal tumors was not prevented in the
Min mouse model fed a Western diet (high fat, low fiber and
calcium) with low and high isoflavones (22). In fact, Rao
et al showed an increase in non-invasive and total adeno-
carcinoma multiplicity in AOM-treated rats fed genistein in a
casein-based diet (22), and McIntosh et al reported that the
number of intestinal tumors was increased with diets
containing soy protein compared to casein (23). Gee et al
observed no suppression of ACF by genistein in the DMH
model of colorectal carcinogenesis (24). However, the data
of Hakkak et al (25) and Thiagarajan et al provide evidence
that soybeans and soy products can reduce the development
of early stages of colon cancer in rats (26). Pereira et al also
found purified genistein to inhibit induction of ACF (27).
Several components of soy other than isoflavones have been
previously reported to reduce chemically induced colon cancer,
but the results are again contradictory. Isoflavones have been
proposed as the most effective constituents for inhibition of
mammary cancer, also possessing antiestrogenic activity
(28-30). Gotoh and associates demonstrated that the
administration of biochanin A, a genistein precursor, inhibits
the development of rat mammary tumors (31). However, we
previously found that it did not reduce colonic ACF induced
by AOM in rats (32). Thus, inhibitory effects of miso against
colorectal and mammary cancers may be due to different
constituents.
We earlier found that prolonged fermentation might be
important for protection against radiation, being associated
with the prolongation of animal survival and decrease in
toxicity to small intestinal crypts (8). It also was associated
with decreased development of ACF (9), lung adenocarcinomas
and gastric tumors (10) and pulmonary adenocarcinomas
(11). Therefore, the fermentation process may produce
cancer-protective substances. Yamamoto et al reported that
the consumption of miso soup but not soyfood, such as soy
beans, tofu, deep fried tofu and nattou, was inversely
associated with the risk of breast cancer in women (33).
Changes in isoflavone constitution during the fermentation
of miso, i.e. conversion of glycosides to unconjugated forms
that might be expected to reduce their anti-carcinogenic
effects, have in fact been reported (34,35). Therefore, the
effective substances may not be just isoflavones. 
In the present study, 180-day fermented miso appeared
linked to a significant decrease of the PCNA-positive index,
which is in line with an earlier report that the BrdU labeling
index with 10% miso supplementation was significantly lower
than that of a normal diet group in AOM-treated rats, and
the length of the germinal region and PCNA-positive index
were reduced by a water soluble extract from cultured medium
of Ganoderma lucidum (Rei-Shi) mycelia (15). Like calcium,
which has been hypothesized to be a regulator of cell
proliferation in the colon and inhibitor of experimental carcino-
genesis (36), ingredients of miso after 180 days fermentation
could act as preventive agents for colon carcinogenesis by
suppressing proliferation.
On the other hand, miso has been revealed to contain
nitrosamine precursors (37-39) that might result in endogenous
formation of N-nitroso compounds in humans. Indeed, in
another study it showed considerable mutagenicity after
nitrite treatment (38,39). Home-made miso is frequently
consumed, and people commonly store their products for
long periods, often for ≥2 years (40), and this could conceivably
increase nitorosamine precursors. Other unknown ingredients
of miso could also naturally be related to cancer risk, and
further comparative studies of ingredients after different
periods of fermentation are clearly warranted.
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Table VIII. Cdx2 staining in colon tumors.
–––––––––––––––––––––––––––––––––––––––––––––––––
Total
cases Positive Negative
–––––––––––––––––––––––––––––––––––––––––––––––––
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Differentiated adenocarcinoma 11 4 (36%) 7 (64%)
Signet ring cell carcinoma 4 1 (25%) 3 (75%)
Total 26 13 13
–––––––––––––––––––––––––––––––––––––––––––––––––
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